razoxane has been researched along with Disease, Pulmonary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chauvenet, A; Constine, LS; De Alarcon, PA; Friedman, D; London, WB; Mendenhall, NP; Schwartz, CL; Sposto, R; Tebbi, CK; Villaluna, D | 1 |
| Ferrans, VJ; Fukuda, Y; Hasinoff, BB; Herman, EH; Raley, LG; Zhang, J; Zhang, TM | 1 |
| Tryka, AF | 1 |
1 trial(s) available for razoxane and Disease, Pulmonary
| Article | Year |
|---|---|
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chelating Agents; Cohort Studies; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid; Lung Diseases; Male; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Osteosarcoma; Razoxane; Risk Assessment; Risk Factors; Thyroid Neoplasms; Time Factors; Topoisomerase II Inhibitors | 2007 |
2 other study(ies) available for razoxane and Disease, Pulmonary
| Article | Year |
|---|---|
Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity.
Topics: Animals; Bleomycin; Ethylenediamines; Female; Glycine; Iron; Lung; Lung Diseases; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Razoxane; Spectrophotometry | 1995 |
ICRF 187 and polyhydroxyphenyl derivatives fail to protect against bleomycin induced lung injury.
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Bleomycin; Cricetinae; Free Radicals; Hydroxamic Acids; Iron Chelating Agents; Lung; Lung Diseases; Male; Mesocricetus; Oxygen; Piperazines; Pulmonary Fibrosis; Razoxane | 1989 |